LACTATED RINGER

Manufacturer
Huaren Pharmaceutical Co., Ltd.
Effective date
2025-08-26
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 21:41:11

Label at a glance#

ProductLACTATED RINGER
Active ingredientCALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE, SODIUM CHLORIDE
Label structure24 sections

Storage and handling

Sealed storage.

Label contents#

Full prescribing information#

SODIUM LACTATE RINGER'S INJECTION, USP BAG

SPL UNCLASSIFIED SECTION

Sodium Lactate Ringer's Injection Instructions

Please read the instructions carefully and use under the guidance of a physician.

Check carefully before use. Do not use if leakage is found, the drug liquid is unclear, or there are visible particles.

INGREDIENTS

DESCRIPTION SECTION

This product is a compound preparation, its components are: sodium lactate 3.10g, sodium chloride 6.00g, potassium chloride 0.30g, calcium chloride (CaCl2·2H2O) 0.2g per 1000ml.

Excipient Name: Sodium Hydroxide

Osmotic Pressure Molar Concentration: 240-270mOsmol/kg

CHARACTER

SPL UNCLASSIFIED SECTION

This product is a colorless and clear liquid.

INDICATIONS

INDICATIONS & USAGE SECTION

Regulating body fluids, electrolytes and acid-base balance regulating drugs. For metabolic acidosis or dehydration cases with metabolic acidosis.

SPECIFICATION

DESCRIPTION SECTION

  • 500ml
  • 1000ml: Sodium lactate 3.10g, sodium chloride 6.00g, potassium chloride 0.30g, calcium chloride 0.20g.

DOSAGE AND USAGE

DOSAGE & ADMINISTRATION SECTION

Intravenous drip. Adult 500ml ~ 1000ml at a time, according to age weight and symptoms can be appropriate to increase or decrease. Administration speed: 300 ~ 500ml per hour for adults.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

  • Patients with hypocalcemia (such as uremia) are prone to numbness, pain, twitching, dyspnea and other symptoms after correcting acidosis, which are often caused by the decrease of calcium ion concentration in the blood;
  • Accelerated heart rate, chest tightness, shortness of breath and other pulmonary edema, heart failure;
  • Elevated blood pressure;
  • Weight gain, edema;
  • Alkalosis occurs when overdose;
  • The concentration of blood potassium decreases, and sometimes hypokalemia appears.

CONTRAINDICATION

CONTRAINDICATIONS SECTION

The following conditions should be contraindicated:

  • Heart failure and acute pulmonary edema;
  • Cerebral edema;
  • Lactic acidosis;
  • Severe hepatic insufficiency;
  • Severe renal failure oliguria or anuria;
  • Hyperkalemia;
  • Severe burn;
  • Addison's disease.

PRECAUTIONS

PRECAUTIONS SECTION

The following cases should be used with caution:

  • Diabetic patients taking biguanides (especially hypoglycemic), hinder the liver's utilization of lactic acid, easy to cause lactic acid poisoning;
  • Edema patients with a tendency to sodium retention;
  • Hypertension patients can increase blood pressure;
  • Heart dysfunction;
  • The rate of lactic acid degradation is slowed down when liver function is not complete, so as to delay the correction speed of acidosis;
  • Hypoxia and shock, insufficient tissue blood supply and hypoxia when lactic acid oxidation into pyruvate into tricarboxylic acid cycle metabolism slowed down, so as to delay the correction speed of acidosis;
  • Alcoholism, salicylic acid poisoning, type I glycogen deposition disease have lactic acidosis tendency, it is not appropriate to use sodium lactate to correct the acid-base balance;
  • When diabetic ketoacidosis acetoacetic acid, β-hydroxybutyric acid and lactic acid are increased, and often accompanied by poor circulation or insufficient blood supply of organs, lactic acid degradation rate is slowed down;
  • Renal insufficiency, prone to water and sodium retention, increase cardiovascular load.

The following tests and observations should be made during medication:

  • Blood pH and/or carbon dioxide binding force;
  • Serum sodium, potassium, calcium, chlorine concentration determination;
  • Determination of renal function, including creatinine, urea nitrogen, etc.;
  • Blood pressure;
  • Cardiopulmonary function status, such as edema, shortness of breath, cyanosis, pulmonary rale, jugular vein filling, hepato-jugular vein regurgitation, venous pressure or central venous pressure measurement as needed;
  • Liver insufficiency performance jaundice, change of mind, ascites, etc., applied before and after sodium lactate and in the application process, often observed at any time.

MEDICATION IN PREGNANT WOMEN AND LACTATING WOMEN

PREGNANCY SECTION

Pregnant women with gestational poisoning may aggravate edema, increase blood pressure, should be used with caution.

MEDICATION IN CHILDREN

PEDIATRIC USE SECTION

The dosage should be calculated according to age, weight and condition.

MEDICATION IN THE ELDERLY

GERIATRIC USE SECTION

Elderly patients often have hidden cardiac and renal insufficiency, which should be used with caution.

DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

When combined with other drugs, pay attention to the incompatibility of drugs (such as macrolide antibiotics, alkaloids, sulfonamides) due to changes in pH and ionic strength. Because this product contains calcium ions, it will precipitate when mixed with blood containing sodium citra

DRUG OVERDOSE

OVERDOSAGE SECTION

An overdose may result in edema or ion imbalance in the body.

PHARMACOLOGY AND TOXICOLOGY

CLINICAL PHARMACOLOGY SECTION

This product can regulate body fluid volume and osmotic pressure, and can supplement potassium, sodium, calcium and chloride ions. Among them, sodium lactate is converted into bicarbonate ion in the body to regulate acid-base balance and maintain normal physiological functions; Na+is the most important cation in extracellular fluid, which is the main substance for maintaining constant osmotic pressure and extracellular volume of body fluid. K+is the main intracellular cation, which plays an important role in maintaining normal neuromuscular excitability. As a second messenger in the cell, calcium ion is closely related to many functions in the body. Lactate ions can correct metabolic acidosis and allow potassium ions to enter the cell from blood and extracellular fluid. When the amount of circulating blood and interstitial fluid in the body is reduced, this product can be used as a supplementary regulator of interstitial fluid, and has a corrective effect on electrolyte disturbance and acidosis.

PHARMACOKINETICS

PHARMACOKINETICS SECTION

This experiment has not been performed and no reliable references are available.

PACKAGE

HOW SUPPLIED SECTION

  1. Plastic infusion bag (non-PVC co-extruded film, double hard tube, easy to fold, double valve and double plug). 50ml/ bag, 100ml/ bag, 250ml/ bag, 500ml/ bag, 10O0ml/ bag.
  2. Plastic infusion bag (non-PVC co-extruded film, double hard tube, easy to fold, double valve double plug, double aseptic packaging). 50ml/ bag, 100ml/ bag, 250ml/ bag, 500ml/ bag, 1000ml/ bag.

VALIDITY

SPL UNCLASSIFIED SECTION

  1. The product of 50ml,100ml, and 1000ml specifications is valid for 24 months.
  2. The validity period of 250ml,500ml is 36 months.

STORAGE

STORAGE AND HANDLING SECTION

Sealed storage.

OTHER INFORMATION

SPL UNCLASSIFIED SECTION

[Package]

Plastic infusion bag (non-PVC co-extruded film, double hard tube, easy to break apart , double valve and double plug). 500ml/ bag, 1000ml/ bag.

[Validity] 24 months

[Executive standard] Pharmacopoeia of the People's Republic of China (2020, Volume II)

[Pharmaceutical marketing authorization holder] Name: Huaren Pharmaceutical Co., Ltd. Registered Address: No. 187, Zhuzhou Road, Qingdao High-tech Park,China

[Manufacturer]

Enterprise Name: Huaren Pharmaceutical Co., Ltd.

Production Address: No. 187, Zhuzhou Road, Qingdao High-tech Park,China

Zip code: 266101

Tel.: 400-0648885 0532-67709071

Fax: 0532-88702625

Website:http//www.qdhuaren.com

HEALTH CARE PROVIDER LETTER pg.1

HEALTH CARE PROVIDER LETTER SECTION

HCP Letter 1HCP Letter 1

HEALTH CARE PROVIDER LETTER pg.2

HEALTH CARE PROVIDER LETTER SECTION

HEALTH CARE PROVIDER LETTER pg.2HEALTH CARE PROVIDER LETTER pg.2

HEALTH CARE PROVIDER LETTER pg.3

HEALTH CARE PROVIDER LETTER SECTION

HEALTH CARE PROVIDER LETTER pg.3HEALTH CARE PROVIDER LETTER pg.3

PACKAGE LABEL– Sodium Lactate Ringer-500 mL Bag Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Sodium Lactate Ringer-500 mL BagSodium Lactate Ringer-500 mL Bag

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9e37788c-b1bf-42ae-aac9-b60601606144Product name820260122
95250459-30e4-45c1-b08a-993044f49109Product name220250805
d9771140-739b-484b-ae64-b79528ff1211Product name320250801
bee4fa8d-8d82-423a-a0b5-40a89dd13a99Product name120250618
e0d2eb29-08bd-4bba-90d1-c91c68a38767Product name420250516
efd58dcf-540a-4531-8766-e713129ca6f2Product name120250307
30b0ac6e-02aa-0e5c-0d8b-cffdf3a282b2Product name520250304
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
1527ac37-808d-43be-a63e-74e1258dbe46Product name920250219
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
334fe8d2-68fb-4331-a576-420e302ec069Product name720240320
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
9fcb7a91-de07-4f00-aabf-e4d6fda403d5Product name820230322
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
0ec3537a-6c9b-432a-896c-b9ea8723049aProduct name920200701
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
e92765c1-be81-432a-b909-1b10777ec378Product name120190208
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
7916de40-e296-41f0-b811-6d0df1a33e2cProduct name920180627
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
0441a8f5-3835-497c-aedd-bc78cba56b2aProduct name120150317
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
85268-80285268-802-02, 85268-802-03

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
430669d7-9ad2-9a04-e063-6394a90ababb33881d79-9b8b-f9dc-e063-6394a90aba812025-11-07Adverse reactionsExact identifier
spl set id: 33881d79-9b8b-f9dc-e063-6394a90aba81

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.